Bob Williamson helped found Aegle in 2013. During his career he started, funded, managed, and/or was a director of over a dozen new companies ranging from the most esoteric medical technologies to industrial valves. He founded venture capital funded Data Net Corporation and was the CFO of Equinox Systems (NASDAQ-EQNX) where he managed its successful purchase by Avocent Corporation. He has served on numerous non-profit boards and currently is a director and treasurer of the St. Martha Concert® series. He has a BS-Engineering and MBA from Stanford.

Aegle’s research team is headed by Dr. Badiavas—a board certified dermatologist and dermatopathologist—whose research has been focused on wound healing, bone marrow, stem cells, bioengineered skin, dermatology, and translational research for more than 30 years. Dr. Badiavas was among the first to describe the trafficking and engraftment of bone marrow cells to wounded skin, and the restoration of skin structures by bone marrow stem cells. He has been the principal investigator on protocols delivering stem cells to wounds for more than 15 years and was the first to describe the delivery of bone marrow stem cells to chronic wounds in humans. Dr. Badiavas has been awarded three IND’s by the FDA for the delivery of stem cells to patients. Having worked in this area for years, he is well versed in all recent regulatory aspects of cell-based therapeutics. His expertise in bone marrow stem cells began as a graduate student in 1982 when he worked on erythroid progenitors under the direction of Alan Erslev, Jaimie Caro and Hideko Kaji. Since then, Dr. Badiavas has completed his PhD, postdoctoral training, medical school, dermatology residency, and dermatopathology fellowship. He is a practicing dermatologist and dermatolopathologist with more than 20 years experience with particular interests in the histologic evaluation of wounds. He has been working with bioengineered skin materials for more than 25 years and has described several key histological features associated with the application of these materials to patients. Dr. Badiavas has also published and presented his findings in several preclinical studies for wounds including rodent and pig models. He has served as a consultant, NIH study section member, and moderator for wound based and stem cell projects. Dr. Badiavas has an extensive and diverse history of close collaboration with several highly regarded stem cell, bone marrow, and wound healing investigators. His unique training and experience allows him to comfortably move between these sometimes-distinct fields.

Elona Baum, Esq, is currently a Managing Director of DEFTA Partners and heads the investment function for its healthcare technologies fund. Ms. Baum’s career spans more than 20 years in drug development, initially at Genentech and then at the California Institute for Regenerative Medicine (CIRM). She has held leadership roles in business development, legal and regulatory. At Genentech she received numerous awards for her leadership and contributions in mergers and acquisitions and in guiding the operations of Genentech’s Spanish subsidiary from its initial purchase, construction, FDA approval and ultimately its sale. Her contributions at Genentech also included negotiation of collaboration and licensing agreements and oversight of the legal functions for Raptiva including patient recruitment in clinical trials, handling of adverse event reporting and agreements with clinical trial sites. At CIRM she oversaw $1 billion of investment in regenerative medicine research and clinical programs, the creation of a $40M induced pluripotent stem cell bank and a re-vamping of intellectual property regulations governing CIRM grants. Ms. Baum currently serves as a member of the Boards of Directors of Endogena Therapeutics, Inc., Abilitech Medical, Inc. and Orig3n, Inc. Early in her career, Ms. Baum practiced law in the litigation and real estate groups of two law firms. She has successfully defended clients and resolved large-scale litigation while in private practice and at Genentech. Ms. Baum served as an extern for Justice Arguelles of the California Supreme Court, graduated Magnum Cum Laude from the University of San Francisco School of Law and graduated Cum Laude from the University of California, Los Angeles with a B.A. in Economics. Ms. Baum has also received a Regulatory Affairs Certification from the Regulatory Affairs Professionals Society.

Shelley Hartman has served as the Chief Executive Officer of Aegle Therapeutics since August of 2014. Prior to Aegle, Ms. Hartman served for nine years as CEO of LifeSync Corporation, a start-up medical device company developing and marketing wireless medical technology to hospital customers. LifeSync was spun-off from LifeSync Holdings (f/k/a GMP Companies, Inc.), a development company focused on biopharmaceutical and medical device product development. Prior to LifeSync, Ms. Hartman served for more than 18 years in the investment banking industry, most recently as Managing Director in the Healthcare Department of the Investment Banking Division at Goldman, Sachs & Co. Ms. Hartman holds a B.A. from Wellesley College.

Lonnie Moulder joined our Board in January 2020. Mr. Moulder is General Partner of Tellus BioVentures, LLC, a life science investment fund he founded in 2019. Previously Mr. Moulder was the co-founder, Chief Executive Officer and a member of the board of directors of TESARO, Inc., a public oncology-focused biopharmaceutical company that was acquired by GlaxoSmithKline plc. Previously Mr. Moulder served as Vice Chairman of the board of directors, President and Chief Executive Officer of Abraxis BioScience, Inc., a biotechnology company. Before that, Mr. Moulder served as Vice Chairman of Eisai Corporation of North America, a pharmaceutical company and wholly owned subsidiary of Eisai Co., Ltd., following Eisai Co., Ltd.’s acquisition of MGI PHARMA, Inc. Mr. Moulder served as President and Chief Executive Officer and as a member of the board of directors of MGI PHARMA, Inc.

Mr. Moulder is a Trustee of Temple University and serves as a board director for several public and privately held biotechnology companies. Mr. Moulder earned a B.S. in pharmacy from Temple University and a M.B.A. from the University of Chicago.

Dr. Robert Ryan is currently the President and CEO of Innova Therapeutics, a company focused on developing innovative therapies for diseases with high unmet needs.

Dr. Ryan has more than 27 years of research/pharmaceutical/biotech experience, spanning the global development process from preclinical through Phase IV. Prior to Innova Therapeutics, Dr. Ryan was the President and CEO of Scioderm, a company he co-founded in 2013. Dr. Ryan led the development of SD-101, a topical therapy for Epidermolysis Bullosa, progressing from pre-IND stage to an ongoing single Phase 3 US/Europe registration study in less than 2 years. Scioderm was the first biotech to receive “Breakthrough Therapy” designation from the FDA. In September 2015, Dr. Ryan led a deal to sell Scioderm to Amicus Therapeutics, with upfront payments and milestones totaling approximately $957 million.

Dr. Ryan’s diverse pharmaceutical career covered senior preclinical, regulatory and clinical activities with Roche, Bristol-Myers Squibb (BMS), UCB, Atherogenics, and Pfizer. In addition Dr. Ryan previously held senior regulatory positions at three of the top five leading CRO’s, PPD, INC Research, and Quintiles. While at Quintiles, Dr. Ryan served as the Chief Regulatory Officer for PharmaBio due diligence team, which was the corporate ventures group that focused on innovative partnering opportunities with pharmaceutical and biotech companies. Selected investment opportunities resulted in investment in excess of $800 million, with a 100% successful track record on deals completed. Prior to working in the pharmaceutical/biotech industry, Dr. Ryan conducted research for several years at the National Institutes of Health's environmental division. Dr. Ryan graduated with a doctorate degree in Toxicology from the University of North Carolina at Chapel Hill, and is board certified in Toxicology. In addition, Dr. Ryan has advanced degreesin Genetics and Pharmacokinetics.

Dr. Schimel joined the Board of Aegle in January of 2020. He practiced internal medicine and endocrinology in the Chicago suburbs and was the cofounder and managing partner of Deerpath Medical Associates, a 30-physician multispecialty group. Dr. Schimel also served as the Director of Midwest Clinical Research Associates and both supervised and participated in a number of Phase 3 and 4 clinical trials in various medical disciplines. After receiving an MBA degree in 1996, Dr. Schimel founded International Equity Trading Partners and managed assets for institutional clients based on a proprietary computer algorithm that predicted the short-term fluctuations of equity and interest rate markets. Dr. Schimel earned a B.S. degree from the University of Illinois, a M.D. degree at the University of Michigan and a M.B.A. from the Kellogg School of Management at Northwestern University.